Who are Eszopiclone (Lunesta)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eszopiclone 1 mg- Elderly, Eszopiclone 3 mg- Non-elderly, Eszopiclone 2 mg- Non-elderly.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eszopiclone-lunesta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Eszopiclone (Lunesta) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eszopiclone (Lunesta) (Eszopiclone (Lunesta)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonbenzodiazepine hypnotic (Z-drug). Area: Neurology / Sleep Medicine.

marketed Nonbenzodiazepine hypnotic (Z-drug) GABA-A receptor (alpha-1 subunit) Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Eszopiclone (Lunesta) (Eszopiclone (Lunesta)) — Sumitomo Pharma America, Inc.. Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Eszopiclone (Lunesta) TARGET	Eszopiclone (Lunesta)	Sumitomo Pharma America, Inc.	marketed	Nonbenzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit)
Eszopiclone 1 mg- Elderly	Eszopiclone 1 mg- Elderly	Eisai Co., Ltd.	phase 3	Nonbenzodiazepine hypnotic (Z-drug)	GABA-A receptor
Eszopiclone 3 mg- Non-elderly	Eszopiclone 3 mg- Non-elderly	Eisai Co., Ltd.	phase 3	Nonbenzodiazepine hypnotic (Z-drug)	GABA-A receptor
Eszopiclone 2 mg- Non-elderly	Eszopiclone 2 mg- Non-elderly	Eisai Co., Ltd.	phase 3	Nonbenzodiazepine hypnotic (Z-drug)	GABA-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonbenzodiazepine hypnotic (Z-drug) class)

Eisai Co., Ltd. · 3 drugs in this class
Sumitomo Pharma America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eszopiclone (Lunesta) — Competitive Intelligence Brief. https://druglandscape.com/ci/eszopiclone-lunesta. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab